Melanoma-associated antigen A8 peptide-Human leukocyte antigen complex (MAGEA8-HLA complex)

The MAGEA8 peptide-HLA complex consists of a specific peptide fragment derived from the Melanoma-associated antigen A8 (MAGEA8) presented on the cell surface by Human Leukocyte Antigen (HLA) molecules, typically HLA-A*02:01. MAGEA8 is a member of the cancer-testis antigen (CTA) family, which is characterized by high expression in various malignancies but restricted expression in normal adult tissues, primarily the testis and placenta. This restricted expression pattern makes the MAGEA8-HLA complex an ideal target for cancer immunotherapies, such as T-cell receptor (TCR) engineered T-cell therapies and bispecific T-cell engagers. When a therapeutic TCR or antibody-like molecule recognizes this complex, it facilitates the targeted destruction of tumor cells by the immune system. Clinical development in this area focuses on ensuring high specificity to avoid cross-reactivity with other MAGE-A proteins that might be expressed in healthy tissues.

Other names

MAGE-A8 peptide-MHC complexCancer/testis antigen 1.8 peptide-HLA complexMAGEA8-HLA-A*02:01 complexMAGEA8-MHC class I complex

T-cell receptor (TCR) binding to the peptide-HLA complex triggers T-cell activation and directed cytotoxicity against tumor cells expressing the MAGEA8 antigen.